Answer
The safety and efficacy of satralizumab have not been studied in patients with hepatic impairment, and no data are available.
Sources for this answer
- Enspryng 120 mg solution for injection in pre-filled syringeRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 3Document updated
Sources checked